Record mula sa primary source
Decision-gradeTopline na resulta
Ipinakita ng Phase 3 VALOR trial ng Pfizer/Valneva na ang PF-07307405 ay may >70% na epekto laban sa Lyme disease
The Phase 3 VALOR trial met its pre-specified secondary efficacy endpoint with 73.2% efficacy from 28 days post-dose 4 and 74.8% from 1-day post-dose 4. Although the primary endpoint's 95% CI lower bound fell short of the pre-specified >20 criterion, Pfizer views the clinically meaningful efficacy as sufficient to proceed with regulatory submissions.
Mahahalagang fact
- Na-file
- Mar 23, 2026, 10:45 AM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
PFEPfizer- Asset
- PF-07307405
- Pinagmulan
- Press release ng kumpanya
- Kumpiyansa
- May source
- edad na grupo
- 5 taon at pataas
- efficacy season2 1d
- 74.8% (95% CI 21.7, 93.9)
- efficacy season2 28d
- 73.2% (95% CI 15.8, 93.5)
Sipi mula sa source
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated with no safety concerns identified at time of analysis Overall, results strengthen confidence in the vaccine candidate and Pfizer is planning submissions to regulatory authorities Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today an